DC Chemicals

All products / DC8546

MI-136
CAT. NO. DC8546

MI-136

Pack sizes and prices

Pack sizePrice
100 mg$650 USDRequest a quote →
250 mg$1,100 USDRequest a quote →
1 g$2,300 USDRequest a quote →

In stock. Contact our team for lead time, shipping and final quotation.

Product overview

MI-136 inhibits DHT-induced expression of androgen receptor (AR) target genes. Target: androgen receptorin vitro: MI-136, a variant of a previously described inhibitor that can specifically inhibit the menin-MLL interaction. AR positive cell lines such as VCaP, LNCaP and 22RV1 are sensitive to MI-136. Treatment with MI-136 also inhibits the expression of genes that were bound to ASH2L after AR stimulation. Treatment with MI-136 induces apoptosis of VCaP cells as evidenced by PARP (cPARP) cleavage. Furthermore, treatment with MI-136 blocks DHT-induced cell proliferation in AR-dependent cell lines (LNCaP and VCaP). The effect of MI-136 on cell proliferation is similar to MDV-3100, a second-generation FDA-approved anti-androgen for patients with refractory prostate cancer. [1]in vivo: Treatment of VCaP tumor-bearing mice with MI-136 (40mg/kg) led to a modest but significant reduction in tumor volume with no effect on mouse body weight. [1]

For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.

Identity and specifications

Catalog numberDC8546
Product nameMI-136
CAS1628316-74-4
Molecular formulaC23N6F3SH21
Molecular weight470.5132
Purity99%
SMILESS1C(C([H])([H])C(F)(F)F)=C([H])C2C1=NC([H])=NC=2N([H])C1([H])C([H])([H])C([H])([H])N(C([H])([H])C2C([H])=C([H])C3=C(C([H])=C(C#N)N3[H])C=2[H])C([H])([H])C1([H])[H]

Source-listed specifications; the batch COA applies.

Source and product documents

The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.

DC Chemicals — MI-136 (DC8546)

Source references

MI-136 inhibits DHT-induced expression of androgen receptor (AR) target genes. Target: androgen receptorin vitro: MI-136, a variant of a previously described inhibitor that can specifically inhibit the menin-MLL interaction. AR positive cell lines such as VCaP, LNCaP and 22RV1 are sensitive to MI-136. Treatment with MI-136 also inhibits the expression of genes that were bound to ASH2L after AR stimulation. Treatment with MI-136 induces apoptosis of VCaP cells as evidenced by PARP (cPARP) cleavage. Furthermore, treatment with MI-136 blocks DHT-induced cell proliferation in AR-dependent cell lines (LNCaP and VCaP). The effect of MI-136 on cell proliferation is similar to MDV-3100, a second-generation FDA-approved anti-androgen for patients with refractory prostate cancer. [1]in vivo: Treatment of VCaP tumor-bearing mice with MI-136 (40mg/kg) led to a modest but significant reduction in tumor volume with no effect on mouse body weight. [1]

Related research products